Recombinant IgG4 monovalent antibodies
View Patent ↗The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.
1. A monovalent IgG4 antibody that binds to a selected antigen, which monovalent antibody comprises:
a heavy chain, which heavy chain comprises:
(i) a human V H region, and
(ii) a human C H region, wherein the C H region has been modified such that the region corresponding to the hinge region does not comprise any amino acid residues which are capable of forming disulfide bonds with an identical C H region, and wherein the C H 3 region has the sequence as set forth in SEQ ID NO: 16, but wherein the C H 3 region has been modified so that one or more of the following amino acid substitutions have been made: Leu (L) in position 236 has been replaced by Ala (A); Leu (L) in position 236 has been replaced by Val (V); Leu (L) in position 236 has been replaced by Glu (E); Leu (L) in position 236 has been replaced by Gly (G); Phe (F) in position 273 has been replaced by Thr (T); Phe (F) in position 273 has been replace by Asp (D); Tyr (Y) in position 275 has been replaced by Ala (A); and Tyr (Y) in position 275 has been replaced by Glu (E) and
a light chain, which light chain comprises:
(i) a human V L region, and
(ii) a human C L region.
2. The monovalent antibody according to claim 1 , wherein the monovalent antibody comprises the CH3 region as set forth in SEQ ID NO: 16, with the exception of the specified amino acid substitutions.
3. The monovalent antibody according to claim 2 , but wherein Leu (L) in position 236 has been replaced by Ala (A).
4. The monovalent antibody according to claim 2 , but wherein Leu (L) in position 236 has been replaced by Val (V).
5. The monovalent antibody according to claim 2 , but wherein Leu (L) in position 236 has been replaced by Glu (E).
6. The monovalent antibody according to claim 2 , but wherein Leu (L) in position 236 has been replaced by Gly (G).
7. The monovalent antibody according to claim 2 , but wherein Phe (F) in position 273 has been replaced by Thr (T) and/or Tyr (Y) in position 275 has been replaced by Glu (E).
8. The monovalent antibody according to claim 2 , but wherein Tyr (Y) in position 275 has been replaced by Ala (A).
9. The monovalent antibody according to claim 2 , wherein the monovalent antibody further comprises the CH2 region as set forth in SEQ ID NO: 16, but wherein Thr (T) in position 118 has been replaced by Gln (Q) and/or Met (M) in position 296 has been replaced by Leu (L).
10. The monovalent antibody according to claim 2 , wherein the monovalent antibody further comprises the CH2 region as set forth in SEQ ID NO: 16, but wherein one, two or all three of the following substitutions have been made: Met (M) in position 120 has been replaced by Tyr (Y); Ser (S) in position 122 has been replaced by Thr (T); and Thr (T) in position 124 has been replaced by Glu (E).
11. The monovalent antibody according to claim 2 , wherein the monovalent antibody further comprises the CH2 region as set forth in SEQ ID NO: 16, but wherein Asn (N) in position 302 has been replaced by Ala (A).
12. The monovalent antibody according to claim 2 , wherein the monovalent antibody further comprises the CH2 region as set forth in SEQ ID NO: 16, but wherein Asn (N) in position 302 has been replaced by Ala (A) and Thr (T) in position 175 has been replaced by Ala (A) and Glu (E) in position 248 has been replaced by Ala (A).
13. The monovalent antibody according to claim 2 , wherein the antigen is selected from VEGF, c-Met, CD20, CD38, IL-8, CD25, CD74, FcalphaRI, FcepsilonRI, acetyl choline receptor, fas, fasL, TRAIL, hepatitis virus, hepatitis C virus, envelope E2 of hepatitis C virus, tissue factor, a complex of tissue factor and Factor VII, EGFr, CD4, and CD28.
14. The monovalent antibody according to claim 2 , wherein the C H 3 region has been modified so that Phe (F) in position 273 has been replaced by Thr (T).
15. The monovalent antibody according to claim 2 , wherein the C H 3 region has been modified so that Phe (F) in position 273 has been replaced by Asp (D).
16. The monovalent antibody according to claim 2 , wherein the C H 3 region has been modified so that Tyr (Y) in position 275 has been replaced by Glu (E).
17. The monovalent antibody according to claim 1 , wherein the C H 3 region has been modified so that Phe (F) in position 273 has been replaced by Thr (T).
18. The monovalent antibody according to claim 1 , wherein the C H 3 region has been modified so that Phe (F) in position 273 has been replaced by Asp (D).
19. The monovalent antibody according to claim 1 , wherein the C H 3 region has been modified so that Tyr (Y) in position 275 has been replaced by Glu (E).
20. The monovalent antibody according to claim 1 , wherein the C H 3 region has been modified so that Tyr (Y) in position 275 has been replaced by Ala (A).
21. The monovalent antibody according to claim 1 , wherein the C H 3 region has been modified so Leu (L) in position 236 has been replaced by Ala (A), Val (V), Leu (L) or Gly (G).
22. The monovalent antibody according to claim 7 , but wherein Phe (F) in position 273 has been replaced by Thr (T) and Tyr (Y) in position 275 has been replaced by Glu (E).
23. The monovalent antibody according to claim 2 , but wherein Phe (F) in position 273 has been replaced by Asp (D) and/or Tyr (Y) in position 275 has been replaced by Glu (E).
24. The monovalent antibody according to claim 23 , but wherein Phe (F) in position 273 has been replaced by Asp (D) and Tyr (Y) in position 275 has been replaced by Glu (E).